SK18132001A3 - Použitie protilátky proti antigénom - Google Patents
Použitie protilátky proti antigénom Download PDFInfo
- Publication number
- SK18132001A3 SK18132001A3 SK1813-2001A SK18132001A SK18132001A3 SK 18132001 A3 SK18132001 A3 SK 18132001A3 SK 18132001 A SK18132001 A SK 18132001A SK 18132001 A3 SK18132001 A3 SK 18132001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- cells
- lymphocytes
- human
- antibodies against
- ltr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI001299A ITMI991299A1 (it) | 1999-06-11 | 1999-06-11 | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
PCT/EP2000/005212 WO2000076542A1 (fr) | 1999-06-11 | 2000-06-07 | Utilisation d'anticorps contre cd20 pour traiter la maladie de rejet du greffon |
Publications (1)
Publication Number | Publication Date |
---|---|
SK18132001A3 true SK18132001A3 (sk) | 2002-05-09 |
Family
ID=11383150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1813-2001A SK18132001A3 (sk) | 1999-06-11 | 2000-06-07 | Použitie protilátky proti antigénom |
Country Status (26)
Country | Link |
---|---|
US (1) | US20070014785A1 (fr) |
EP (1) | EP1185299B1 (fr) |
JP (1) | JP2003501482A (fr) |
KR (1) | KR20020026455A (fr) |
CN (1) | CN1253208C (fr) |
AU (1) | AU774206B2 (fr) |
BG (1) | BG106193A (fr) |
CA (1) | CA2376288A1 (fr) |
CZ (1) | CZ20014450A3 (fr) |
DE (1) | DE60033030T2 (fr) |
DK (1) | DK1185299T3 (fr) |
EE (1) | EE200100667A (fr) |
ES (1) | ES2278616T3 (fr) |
HK (1) | HK1043549B (fr) |
HU (1) | HUP0201600A3 (fr) |
IL (1) | IL146934A0 (fr) |
IS (1) | IS6195A (fr) |
IT (1) | ITMI991299A1 (fr) |
NO (1) | NO20016035L (fr) |
NZ (1) | NZ515992A (fr) |
PL (1) | PL352860A1 (fr) |
PT (1) | PT1185299E (fr) |
SK (1) | SK18132001A3 (fr) |
TR (1) | TR200103581T2 (fr) |
WO (1) | WO2000076542A1 (fr) |
ZA (1) | ZA200110004B (fr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1637160A3 (fr) | 1999-05-07 | 2006-05-03 | Genentech, Inc. | Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes B |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
BRPI0316779B1 (pt) * | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
CN1316019C (zh) * | 2002-12-26 | 2007-05-16 | 中国医学科学院中国协和医科大学血液学研究所血液病医院 | 抗cd20嵌合抗体突变体基因及其应用 |
ES2322267T3 (es) | 2003-04-09 | 2009-06-18 | Genentech, Inc. | Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa. |
KR101412271B1 (ko) | 2003-05-09 | 2014-06-25 | 듀크 유니버시티 | Cd20-특이적 항체 및 이를 이용한 방법 |
KR20060027801A (ko) | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | B 세포 장애에 대한 조합 요법 |
EP1730288B1 (fr) * | 2004-03-22 | 2013-05-15 | The Ohio State University Research Foundation | Methodes permettant de transfecter des cellules tueuses naturelles |
KR20070029733A (ko) | 2004-06-04 | 2007-03-14 | 제넨테크, 인크. | 다발성 경화증의 치료 방법 |
KR100864549B1 (ko) | 2004-08-04 | 2008-10-20 | 어플라이드 몰리큘라 에볼류션, 인코포레이티드 | 변이체 fc 영역 |
CN101223448B (zh) | 2005-05-20 | 2012-01-18 | 健泰科生物技术公司 | 来自自身免疫病受试者的生物学样品的预处理 |
AU2006272597A1 (en) | 2005-07-25 | 2007-02-01 | Emergent Product Development Seattle Llc | Single dose use of CD20-specific binding molecules |
UA97469C2 (uk) | 2005-07-25 | 2012-02-27 | Емерджент Продакт Дівелопмент Сіетл, Елелсі | Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
CN101008291B (zh) * | 2006-01-26 | 2010-05-12 | 金海产品有限公司 | 用于水池清洁机的密封盒装置 |
NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
CA2584494A1 (fr) * | 2007-03-27 | 2008-09-27 | Jeffrey A. Medin | Vecteur codant un polypeptide therapeutique et elements de securite permettant de verifier les cellules transduites |
JP5403752B2 (ja) * | 2007-06-22 | 2014-01-29 | 北海道公立大学法人 札幌医科大学 | 移植片対宿主疾患の検査および治療方法 |
LT3597659T (lt) | 2007-07-09 | 2023-05-10 | Genentech, Inc. | Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu |
WO2009018411A1 (fr) | 2007-07-31 | 2009-02-05 | Regeneron Pharmaceuticals, Inc. | Anticorps humains en cd20 humain et leur procédé d'utilisation |
AU2008312406B2 (en) | 2007-10-16 | 2014-03-06 | Ares Trading S.A. | Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease |
EP2077281A1 (fr) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique |
WO2009114942A1 (fr) | 2008-03-20 | 2009-09-24 | University Health Network | Fusions de thymidylate kinase et leurs utilisations |
NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
WO2010075249A2 (fr) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b |
SG178358A1 (en) | 2009-08-11 | 2012-03-29 | Genentech Inc | Production of proteins in glutamine-free cell culture media |
EP2533810B1 (fr) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Anticorps anti-cd20 et utilisations de ceux-ci |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
PL3221359T3 (pl) | 2014-11-17 | 2020-11-16 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20 |
PT3303373T (pt) | 2015-05-30 | 2020-07-14 | Molecular Templates Inc | Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas |
LT3313879T (lt) | 2015-06-24 | 2022-03-25 | F. Hoffmann-La Roche Ag | Antikūnai prieš transferino receptorių su pritaikytu giminingumu |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
TWI819458B (zh) | 2015-10-02 | 2023-10-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
EP4252629A3 (fr) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal |
EP3600416B1 (fr) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable |
WO2019246312A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un immunomodulateur |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
CA3110513A1 (fr) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Strategie de dosage permettant d'attenuer le syndrome de liberation de cytokines pour des anticorps bispecifiques cd3/c20 |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5272082A (en) * | 1992-03-30 | 1993-12-21 | The Wistar Institute Of Anatomy & Biology | Cytotoxic T-ALL cell lines and uses therefor |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
IL127211A0 (en) * | 1996-05-31 | 1999-09-22 | Genetic Therapy Inc | Prevention of graft-versus-host disease with t-cells including polynucleotides encoding negative selective markers |
GB9705744D0 (en) * | 1997-03-20 | 1997-05-07 | Davies Alison M | Methods for selecting cells and their uses |
-
1999
- 1999-06-11 IT IT1999MI001299A patent/ITMI991299A1/it unknown
-
2000
- 2000-06-07 CZ CZ20014450A patent/CZ20014450A3/cs unknown
- 2000-06-07 WO PCT/EP2000/005212 patent/WO2000076542A1/fr active IP Right Grant
- 2000-06-07 EP EP00940332A patent/EP1185299B1/fr not_active Expired - Lifetime
- 2000-06-07 KR KR1020017015954A patent/KR20020026455A/ko active IP Right Grant
- 2000-06-07 CN CNB008088330A patent/CN1253208C/zh not_active Expired - Fee Related
- 2000-06-07 CA CA002376288A patent/CA2376288A1/fr not_active Abandoned
- 2000-06-07 PT PT00940332T patent/PT1185299E/pt unknown
- 2000-06-07 SK SK1813-2001A patent/SK18132001A3/sk unknown
- 2000-06-07 NZ NZ515992A patent/NZ515992A/xx unknown
- 2000-06-07 AU AU55303/00A patent/AU774206B2/en not_active Ceased
- 2000-06-07 IL IL14693400A patent/IL146934A0/xx unknown
- 2000-06-07 TR TR2001/03581T patent/TR200103581T2/xx unknown
- 2000-06-07 DK DK00940332T patent/DK1185299T3/da active
- 2000-06-07 DE DE60033030T patent/DE60033030T2/de not_active Expired - Fee Related
- 2000-06-07 PL PL00352860A patent/PL352860A1/xx not_active IP Right Cessation
- 2000-06-07 HU HU0201600A patent/HUP0201600A3/hu unknown
- 2000-06-07 JP JP2001502875A patent/JP2003501482A/ja active Pending
- 2000-06-07 ES ES00940332T patent/ES2278616T3/es not_active Expired - Lifetime
- 2000-06-07 EE EEP200100667A patent/EE200100667A/xx unknown
-
2001
- 2001-12-05 ZA ZA200110004A patent/ZA200110004B/xx unknown
- 2001-12-07 BG BG106193A patent/BG106193A/bg unknown
- 2001-12-10 IS IS6195A patent/IS6195A/is unknown
- 2001-12-10 NO NO20016035A patent/NO20016035L/no not_active Application Discontinuation
-
2002
- 2002-07-22 HK HK02105388.7A patent/HK1043549B/zh not_active IP Right Cessation
-
2006
- 2006-08-03 US US11/498,103 patent/US20070014785A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070014785A1 (en) | 2007-01-18 |
CA2376288A1 (fr) | 2000-12-21 |
PT1185299E (pt) | 2007-03-30 |
HK1043549A1 (en) | 2002-09-20 |
DE60033030T2 (de) | 2007-05-31 |
JP2003501482A (ja) | 2003-01-14 |
HUP0201600A3 (en) | 2005-04-28 |
DK1185299T3 (da) | 2007-05-21 |
AU774206B2 (en) | 2004-06-17 |
EP1185299A1 (fr) | 2002-03-13 |
IS6195A (is) | 2001-12-10 |
CZ20014450A3 (cs) | 2002-04-17 |
TR200103581T2 (tr) | 2002-08-21 |
WO2000076542A1 (fr) | 2000-12-21 |
ITMI991299A0 (it) | 1999-06-11 |
DE60033030D1 (de) | 2007-03-08 |
HK1043549B (zh) | 2006-09-01 |
AU5530300A (en) | 2001-01-02 |
CN1355712A (zh) | 2002-06-26 |
CN1253208C (zh) | 2006-04-26 |
PL352860A1 (en) | 2003-09-08 |
NO20016035L (no) | 2002-02-11 |
NZ515992A (en) | 2004-01-30 |
IL146934A0 (en) | 2002-08-14 |
EP1185299B1 (fr) | 2007-01-17 |
EE200100667A (et) | 2003-02-17 |
ES2278616T3 (es) | 2007-08-16 |
NO20016035D0 (no) | 2001-12-10 |
HUP0201600A2 (en) | 2002-08-28 |
ITMI991299A1 (it) | 2000-12-11 |
KR20020026455A (ko) | 2002-04-10 |
BG106193A (bg) | 2002-08-30 |
ZA200110004B (en) | 2003-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1185299B1 (fr) | Utilisation d'anticorps contre cd20 pour traiter la maladie de rejet du greffon | |
AU2019203823B2 (en) | CS1-specific chimeric antigen receptor engineered immune effector cells | |
Serafini et al. | Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease | |
US20120100156A1 (en) | Therapeutic Agent | |
WO2018145649A1 (fr) | Construction d'un récepteur d'antigène chimère ciblant un antigène cd20 et identification d'activité de lymphocytes t génétiquement modifiées de celui-ci | |
US11001639B2 (en) | Chimeric antigen receptor for efficient selective proliferation in vitro and uses thereof | |
CN108864286B (zh) | 靶向cd19的嵌合抗原受体及联合表达抗pd1抗体可变区的方法和及其用途 | |
CN110606893A (zh) | 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法 | |
CN113755448B (zh) | 联合表达CCR2b和CD40L的工程化免疫细胞及其制备和应用 | |
EP1578897A2 (fr) | Technique permettant d'induire une tolerance fonctionnelle a des produits de transfert genique | |
CN109750067A (zh) | 分泌型抗免疫检查点抗体及tEGFR分子共表达的细胞及其应用 | |
CN109750066A (zh) | 分泌型抗免疫检查点抗体、胞内免疫检查点抑制分子及tEGFR分子的共表达及其应用 |